Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.51 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253984 | 0.95 | PTPN12 (0.50) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL5254121 | 0.94 | PTPN12 (0.49) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL5247483 | 0.93 | PTPN12 (0.49) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL5251584 | 0.91 | PTPN12 (0.49) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL6796700 | 0.90 | PTPN12 (0.49) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL6798377 | 0.89 | PTPN12 (0.55) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL6796892 | 0.88 | PTPN12 (0.50) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL6708335 | 0.88 | PTPN12 (0.48) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL6764834 | 0.88 | PTPN12 (0.48) | PTPN12PTPN22HTTMEN1MAPT | |
| SCHEMBL5251378 | 0.87 | PTPN12 (0.48) | PTPN12PTPN22HTTMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036078-B1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | US | disclosed |
| US-20040034040-A1 | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1355649-A2 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES | MERCK PATENT GmbH (DE) | 2003-10-29 | — | — | EP | disclosed |
| EP-1347761-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1337256-A2 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| US-6495554-B2 | PHOSPHODIESTERASE V INHIBITORS, TREATING CARDIOVASCULAR DISORDERS, AND THERAPY OF ERECTILE DYSFUNCTION. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020132818-A1 | Thienopyrimidines | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002060449-A2 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINE AND NITRATES OR THIENOPYRIMIDINES AND NITRATES | MERCK PATENT GMBH (DE) | 2002-08-08 | — | — | WO | disclosed |
| US-6420368-B1 | DISEASES OF THE CARDIOVASCULAR SYSTEM AND FOR TREATMENT AND/OR THERAPY OF ERECTILE DYSFUNCTION. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-07-16 | — | — | US | disclosed |
| WO-2002049650-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002041896-A2 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2002-05-30 | — | — | WO | disclosed |
| EP-1036078-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028325-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | PTPN12 1903/4885PTPN22 1940/4885HTT 3846/4885 |
| US-20040034040-A1 | Use of thienopyrimidines | DPYD, TBXAS1, TYMS | PTPN12 2001/4885PTPN22 1670/4885HTT 3761/4885 |
| US-20020132818-A1 | Thienopyrimidines | PDE5A, PDE3B, PDE3A | PTPN12 1259/4885PTPN22 1102/4885HTT 3015/4885 |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | PTGER1, TBXA2R, PTGIS | PTPN12 2786/4885PTPN22 2788/4885HTT 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.